Stereotactic ablative radiation therapy for extracranial metastases from malignant melanoma: An international multi-institutional analysis.
Authors:
- 1 January 2025
- journal article
- Vol. 9 (3) , 199-205
Abstract
To report on local control (LC), toxicity, and overall survival (OS) following stereotactic ablative radiation therapy (SABR) for extracranial metastases from malignant melanoma. The RSSearch® Patient Registry was searched for patients with extracranial melanoma metastases treated with SABR. LC was defined as the time from completion of SABR to the date of last radiographic follow-up with either stability or decrease in size of the treated metastasis or the date at which lesion growth was radiographically confirmed per RECIST criteria. Kaplan-Meier analyses were utilized to evaluate potential prognostic factors on univariate analyses (UVA) with log-rank tests followed by use of a Cox proportional hazards multivariate (MVA) model. There were 45 patients with 52 extracranial melanoma metastases treated with SABR. One- and 2-year LC rates were both 85.3% (95% CI: 67.9-93.7%) following SABR. On UVA, BED10 < 60 Gy was associated with poorer 1-year and 2-year LC (96% vs. 61.9%), which remained significant on MVA (hazard ratio [HR] = 7.06; p = 0.03). On UVA, pulmonary vs. non-pulmonary metastases were correlated with 1-year OS (84.5% vs. 57.4%; p = 0.05) and non-spinal vs. spinal metastases (74.3% vs. 56.3%; p = 0.02), though neither were significant on MVA. The incidence of treatment-related toxicity was 18.9%, all Grade 1-2. We recommend dose/fractionation schedules that meet or exceed BED10 ≥ 60 Gy when treating extracranial melanoma metastases with SABR.Keywords
This publication has 27 references indexed in Scilit:
- Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcomaJournal of Neurosurgery, 2008
- A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanomaCancer, 2007
- Radiosurgery for Spinal MetastasesSpine, 2007
- Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397)Journal of Clinical Oncology, 2005
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survivalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Fraction size in external beam radiation therapy in the treatment of melanomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1991
- A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1985
- The radiosensitivity of melanoma cells in cultureBritish Journal of Radiology, 1971
- The radiation response of human malignant melanoma cells grown in vitro.1971